


HDx | Worldwide Evidence

Delivering meaningful innovation through evidence-based therapy



A robust evidence generation effort underpins meaningful innovation.

Outcomes (Hard)

Economic

Patient-Reported Outcomes

Clinical Effectiveness

Performance

Safety

✓ PATIENT-REPORTED OUTCOMES

Restless Leg Syndrome criteria are reduced approximately 50% after 6 months for prevalent HD patients in a large observational study by Baxter.⁴ A smaller before-after study found no difference in patient-reported symptom burden.²

✓ CLINICAL EFFECTIVENESS

Pre-dialysis levels of beta 2 microglobulin and kappa and lambda free light chains were reduced after 3 and 6 months with HDx therapy using the MCO dialyzer in a multi-centric observational study of 41 HD patients.³

✓ PERFORMANCE

Theranova provides superior removal of large middle molecules (25 kDa to < 60 kDa) compared to conventional HD and high-volume HDF modalities.¹

✓ SAFETY


Albumin removal during HDx treatment is 3 grams on average and limited to between 1 and 4 grams per treatment.¹ Further, HDx therapy does not impact plasma albumin level to a clinically significant extent.²

1 – Kirsch AH, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transpl 2017; 32(1):165-72;

2 – Krishnasamy R et al. Trial evaluating mid cut-off value membrane clearance of albumin and light chains in hemodialysis patients (REMOVAL-HD): a safety and efficacy study. ASN 2018 Kidney Week Abstract TH-P0353

3 – Cantaluppi V et al. Removal of large-middle molecules on expanded hemodialysis (HDx): a multicentric observational study of 6 months follow-up. ASN 2018 Kidney Week Abstract TH-P0357

4 – Sanabria M et al. Quality of life reported by patients with expanded hemodialysis by the Theranova dialyzer in RTS Colombia. ASN 2018 Kidney Week Abstract TH-P0296



Outcomes (Hard)

Economic

Patient-Reported Outcomes

Clinical Effectiveness

Performance

Safety

2020

- Penny, J.D., Salerno, F.R., Akbari, A. and McIntyre, C.W. (2020), Pruritus: Is there a grain of salty truth?. Hemodialysis International. doi: <https://doi.org/10.1111/hdi.12885>
- Weiner, D.E., Falzon, L., Skoufos, L., Bernardo, A., Beck, W., Xiao, M., Tran, H., Efficacy and Safety of Expanded Hemodialysis with the TheraNova 400 Dialyzer. CJASN Sep 2020, 15 (9) 1310-1319; DOI: <https://doi.org/10.2215/CJN.01210120>
- Ronco C, Reis T, Cozzolino M: Rationale for Medium Cutoff Membranes in COVID-19 Patients Requiring Renal Replacement Therapy. Nephron 2020. doi: <https://doi.org/10.1159/000509807>
- Penny, J.D., Salerno, F.R., Hur, L., McIntyre, C.W., P1062 EXPANDED DIALYSIS (HDx): IS THERE AN IMPACT ON PATIENT REPORTED SYMPTOM?, Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_3, June 2020, gfaa142.P1062, <https://doi.org/10.1093/ndt/gfaa142.P1062>
- Lim, J., Park, Y., Yook, J. et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients. Sci Rep 10, 7780 (2020). <https://doi.org/10.1038/s41598-020-64622-z>
- Kim T. H. et al: Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study; BMC Nephrology, 2020; 21:2; doi: <https://doi.org/10.1186/s12882-019-1669-3>
- Krishnasamy R. et al: A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study, Blood Purif. 2020 Jan 22;1-11; doi: <https://doi.org/10.1159/000505567>
- Belmouaz M. et al: Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialyzers: a randomized clinical trial, Nephrol Dial Transplant, 2020, 35: 328–335; doi: <https://doi.org/10.1093/ndt/gfz189>

2019

- Cantaluppi et al., Removal of large-middle molecules, inhibition of neutrophil activation and modulation of inflammation related endothelial dysfunction during expanded hemodialysis (HDx), Nephrol Dial Transplant, 2019; 34, Supplement 1.; <https://doi.org/10.1093/ndt/gfz096.F0048>
- Cho et al: Long-term effect of medium cut-off dialyzer on middle uremic toxins and cell-free hemoglobin, PLoS ONE, 2019; 14(7): <https://doi.org/10.1371/journal.pone.0220448>
- Cozzolino et al: Effects of a medium cut-off (TheraNova) dialyser on haemodialysis patients: a prospective, cross-over study, Clin Kidney J, 2019; <https://doi.org/10.1093/ckj/sfz155>
- Maduell F. et al: Comparison of Solute Removal Properties Between High-Efficient Dialysis Modalities in Low Blood Flow Rate, Ther Apher Dial, 2019; <https://doi.org/10.1111/1744-9987.13440>

2018

- Belmouaz M. et al: Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle size molecules, Clinical Nephrol 2018; 89 (1): 50-56; doi: <https://doi.org/10.5414/cn109133E2%80%A9>
- García-Prieto Ana. et al: Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialyzers in conventional haemodialysis and online haemodiafiltration, Clinical Kidney Journal, 2018; <https://doi.org/10.1093/ckj/sfy004/4909823>
- Gernone G. et al: Mid-term evaluation of the new medium cut-off filter (TheraNova®) on removal efficiency and quality of life, Abstract SP489, ERA-EDTA 2018
- Ronco C and Clark WR: Haemodialysis membranes, Nat Rev Nephrol 2018;May 5; doi: <https://doi.org/10.1038/s41581-018-0002-x>
- Cantaluppi V et al. Removal of large-middle molecules on expanded hemodialysis (HDx): a multicentric observational study of 6 months follow-up. ASN 2018 Kidney Week Abstract TH-PO357
- Sanabria M. et al: Quality of life reported by patients with expanded hemodialysis by the TheraNova dialyzer in RTS Colombia. ASN 2018 Kidney Week Abstract TH-PO296.
- Schepers E. et al: Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up, BMC Nephrology 2018; 19:1; doi: <https://dx.doi.org/10.1186%2Fs12882-017-0808-y>
- Wolley M. et al: Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules, CJASN 2018;13:805-814; doi: <https://doi.org/10.2215/CJN.10110917>

2017

- Zickler et al: Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients - A Randomized Controlled Clinical Trial, PLoS ONE, 2017; 13;12(1):doi: <https://doi.org/10.1371/journal.pone.0169024>
- Zweigart C. et al: Medium cut-off membranes – closer to the natural kidney removal function, Int J Artif Organs 2017; 40(7):328-334; doi: <https://dx.doi.org/10.5301%2Fijao.5000603>
- Hutchison CA, Wolley M. The Rationale for Expanded Hemodialysis Therapy (HDx). Contrib Nephrol. 2017;191:142-152. doi: <https://doi.org/10.1159/000479262>
- Ronco C.: The Rise of Expanded Hemodialysis, Blood Purif. 2017;44:I–VIII; doi: <https://doi.org/10.1159/000476012>
- Kirsch H. et al: Performance of hemodialysis with novel medium cut-off dialyzers, Nephrol Dial Transplant. 2017; 32:165-172; doi: <https://dx.doi.org/10.1093%2Fndt%2Fgfw310>